Journal of Clinical Psychopharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Seizure After COVID-19 Vaccination in a Patient on Clozapine
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Letters to the Editors – Case Reports Source Type: research

Further Studies of Effects of Finasteride on Mood and Suicidal Risk
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Letter to the Editors – Research Report Source Type: research

Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review
Conclusions Most studies showed a minimum LAM threshold level of 3 μg/mL in patients with mood disorders; however, the data are inconsistent regarding the therapeutic range for LAM. Based on the pooled data, there is inconsistent evidence to make conclusive recommendations on therapeutic LAM serum levels for mood improvement. Further studies including larger sample sizes are required to address this relevant clinical question. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Brief Reports Source Type: research

Olanzapine Reduction From High Dose to Standard Dose: A Retrospective Chart Review
Conclusions The findings suggest that high-dose olanzapine can be reduced to the standard dose after stabilization of symptoms in most patients with schizophrenia. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Brief Reports Source Type: research

Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study
Conclusions Our follow-up results suggest that the combination of quetiapine and ketamine can prolong time to relapse after ketamine treatment in patients with treatment-resistant disorder. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Brief Reports Source Type: research

CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, With First Episode Psychosis
Conclusions Our results do not support routine use of CYP2D6 testing as a predictor of drug-induced parkinsonism or akathisia risk in clinical settings. Further studies with larger samples of CYP2D6 poor metabolizers are needed. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Brief Reports Source Type: research

Olanzapine-Related Somnambulism: A Systematic Review of Literature and a Case Report of Anorexia Nervosa
Conclusions To provide a reliable estimate of incidence and prevalence for olanzapine-related somnambulism, large-scale, pharmacovigilance studies are required, to allow for comparisons of overall clinical characteristics, outcomes, including time to recovery, between different treatment options. Clinician awareness should be enhanced, and attention should be given to such infrequent adverse effects associated with antipsychotics. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019: The Impact of Second-Generation Antipsychotics
Conclusions More effort is needed to prevent unintentional deaths not only from clozapine but also from olanzapine and quetiapine. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

The Effect of Adding Memantine to Clonidine in Reducing Withdrawal Symptoms in Opioid-Dependent Patients: A Double-Blind Randomized Controlled Trial
Conclusions No specific advantage of memantine was found for reducing the symptoms of withdrawal syndrome in the present study. However, this drug was well tolerated without any evidence of serious or significant adverse effects. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole
The objective of this study was to investigate whether use of aripiprazole in its long-acting injectable formulation (ALAI), during a 3-month treatment, has beneficial effects on CBF and cognitive functioning in patients with first episode of schizophrenia. Methods/Procedures Single-photon emission computed tomography with technetium-99m hexamethylpropylene amine oxime was performed at 2 time points. Cognitive functions were assessed with a standardized test for cognitive functions, 5-KOG test, whereas severity of clinical symptoms was assessed with the Positive and Negative Syndrome Scale, both at the same 2 time p...
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
Conclusions Miricorilant may provide a promising option for ameliorating the detrimental effects of olanzapine, and investigation of this medication in patients affected by antipsychotic-induced weight gain is warranted. Two phase 2 studies of miricorilant in patients with recent and long-standing antipsychotic-induced weight gain are currently in progress. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia
Conclusions The results demonstrate the efficacy of bupropion, compared with placebo, in patients maintained on chronic treatment with olanzapine or risperidone, both known to be major contributors to significant weight gain. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital
Conclusions These findings show that cannabis and alcohol are largely abused and coabused by psychotic patients with a propsensity for violence, but only alcohol is associated with impulsive and violent behavior. Therefore, especially alcohol abuse should be seriously considered by practitioners when evaluating the dangerousness of patients with schizophrenia spectrum disorders. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Original Contributions Source Type: research

Journal of Clinical Psychopharmacology Updates
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Editor's Notes Source Type: research

How Homogeneous Are Diagnostic Groups?
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - November 1, 2021 Category: Psychiatry Tags: Commentary Source Type: research